Prospera Financial Services’s Corbus Pharmaceuticals CRBP Stock Holding History

Prospera Financial Services’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33	Closed	-$1K	–	1796
2022 Q1	$1K	Buy	+33	New	+$437	﹤0.01%	2584
2020 Q4	–	Sell	-83	Closed	-$5K	–	843
2020 Q3	$5K	Buy	+83	New	+$15K	﹤0.01%	1276
2020 Q1	–	Sell	-760	Closed	-$124K	–	528
2019 Q4	$124K	Sell	760 -117	-13%	-$17.3K	0.01%	584
2019 Q3	$128K	Hold	877	–	–	0.01%	531
2019 Q2	$182K	Buy	877 +434	+98%	+$92.9K	0.02%	498
2019 Q1	$97K	Buy	+443	New	+$97.7K	0.03%	315

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Prospera Financial Services's CRBP Position: Q2 2022 in Review

Prospera Financial Services sold out of Corbus Pharmaceuticals (CRBP) in Q2 2022, closing a stake of 33 shares — an estimated $1K sold.

Prospera Financial Services first reported a position in CRBP in Q1 2019 and held it in 6 quarters. The position peaked at $182K in Q2 2019. 70 funds tracked by Wall St. Rank hold CRBP as of Q2 2022.

Prospera Financial Services reported no remaining Corbus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Prospera Financial Services sold 33 Corbus Pharmaceuticals shares in Q2 2022, an estimated $1K.
Prospera Financial Services first reported a position in Corbus Pharmaceuticals in Q1 2019 and held it in 6 quarters.
Prospera Financial Services's Corbus Pharmaceuticals position peaked at $182K in Q2 2019.
70 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.